Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses
Multiple Sclerosis (MS) is a demyelinating autoimmune disorder of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) has been widely used to determine the pathogenesis of the disease and evaluate new treatment strategies for MS. Therefore, we investigated the efficacy...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/44/11/388 |
| _version_ | 1827644753546575872 |
|---|---|
| author | Dariush Haghmorad Bahman Yousefi Majid Eslami Ali Rashidy-Pour Mahdieh Tarahomi Maryam Jadid Tavaf Azita Soltanmohammadi Simin Zargarani Aleksandr Kamyshnyi Valentyn Oksenych |
| author_facet | Dariush Haghmorad Bahman Yousefi Majid Eslami Ali Rashidy-Pour Mahdieh Tarahomi Maryam Jadid Tavaf Azita Soltanmohammadi Simin Zargarani Aleksandr Kamyshnyi Valentyn Oksenych |
| author_sort | Dariush Haghmorad |
| collection | DOAJ |
| description | Multiple Sclerosis (MS) is a demyelinating autoimmune disorder of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) has been widely used to determine the pathogenesis of the disease and evaluate new treatment strategies for MS. Therefore, we investigated the efficacy of oral administration of a Myelin Oligodendrocyte Glycoprotein (MOG) in the treatment of EAE. Female C57BL/6 mice were utilized in three groups (Control group, received PBS orally; prevention group, oral administration of MOG<sub>35–55</sub> two weeks before EAE induction; treatment group, oral administration of MOG<sub>35–55</sub> after EAE induction). MOG administration, both as prevention and treatment, significantly controlled clinical score, weight loss, CNS inflammation, and demyelination, mainly through the modulation of T cell proliferation, and reduction in pro-inflammatory cytokines and transcription factors, including TNF-α, IFN-γ, IL-17, T-bet, and ROR-γt. MOG administration, both as prevention and treatment, also induced anti-inflammatory cytokines and transcription factors, including IL-4, TGF-β, GATA-3, and Foxp3. The results showed that oral administration of MOG, both as prevention and treatment, could efficiently control EAE development. Immunomodulatory mechanisms include the induction of Th2 and Treg cells and the suppression of pro-inflammatory Th1 and Th17 cells. |
| first_indexed | 2024-03-09T18:24:50Z |
| format | Article |
| id | doaj.art-cb0a7d49550c4b7e84d1087705e14c52 |
| institution | Directory Open Access Journal |
| issn | 1467-3037 1467-3045 |
| language | English |
| last_indexed | 2024-03-09T18:24:50Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj.art-cb0a7d49550c4b7e84d1087705e14c522023-11-24T08:01:09ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452022-11-0144115728574010.3390/cimb44110388Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune ResponsesDariush Haghmorad0Bahman Yousefi1Majid Eslami2Ali Rashidy-Pour3Mahdieh Tarahomi4Maryam Jadid Tavaf5Azita Soltanmohammadi6Simin Zargarani7Aleksandr Kamyshnyi8Valentyn Oksenych9Cancer Research Center, Semnan University of Medical Sciences, Semnan 35131, IranCancer Research Center, Semnan University of Medical Sciences, Semnan 35131, IranDepartment of Bacteriology and Virology, Semnan University of Medical Sciences, Semnan 35131, IranResearch Center of Physiology, Semnan University of Medical Sciences, Semnan 35131, IranDepartment of Immunology, Semnan University of Medical Sciences, Semnan 35131, IranDepartment of Immunology, Semnan University of Medical Sciences, Semnan 35131, IranDepartment of Immunology, Semnan University of Medical Sciences, Semnan 35131, IranDepartment of Immunology, Semnan University of Medical Sciences, Semnan 35131, IranDepartment of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, UkraineInstitute of Clinical Medicine, University of Oslo, 0318 Oslo, NorwayMultiple Sclerosis (MS) is a demyelinating autoimmune disorder of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) has been widely used to determine the pathogenesis of the disease and evaluate new treatment strategies for MS. Therefore, we investigated the efficacy of oral administration of a Myelin Oligodendrocyte Glycoprotein (MOG) in the treatment of EAE. Female C57BL/6 mice were utilized in three groups (Control group, received PBS orally; prevention group, oral administration of MOG<sub>35–55</sub> two weeks before EAE induction; treatment group, oral administration of MOG<sub>35–55</sub> after EAE induction). MOG administration, both as prevention and treatment, significantly controlled clinical score, weight loss, CNS inflammation, and demyelination, mainly through the modulation of T cell proliferation, and reduction in pro-inflammatory cytokines and transcription factors, including TNF-α, IFN-γ, IL-17, T-bet, and ROR-γt. MOG administration, both as prevention and treatment, also induced anti-inflammatory cytokines and transcription factors, including IL-4, TGF-β, GATA-3, and Foxp3. The results showed that oral administration of MOG, both as prevention and treatment, could efficiently control EAE development. Immunomodulatory mechanisms include the induction of Th2 and Treg cells and the suppression of pro-inflammatory Th1 and Th17 cells.https://www.mdpi.com/1467-3045/44/11/388Multiple Sclerosisexperimental autoimmune encephalomyelitisMyelin Oligodendrocyte GlycoproteinImmunomodulatory mechanisms |
| spellingShingle | Dariush Haghmorad Bahman Yousefi Majid Eslami Ali Rashidy-Pour Mahdieh Tarahomi Maryam Jadid Tavaf Azita Soltanmohammadi Simin Zargarani Aleksandr Kamyshnyi Valentyn Oksenych Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses Current Issues in Molecular Biology Multiple Sclerosis experimental autoimmune encephalomyelitis Myelin Oligodendrocyte Glycoprotein Immunomodulatory mechanisms |
| title | Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses |
| title_full | Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses |
| title_fullStr | Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses |
| title_full_unstemmed | Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses |
| title_short | Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses |
| title_sort | oral administration of myelin oligodendrocyte glycoprotein attenuates experimental autoimmune encephalomyelitis through induction of th2 treg cells and suppression of th1 th17 immune responses |
| topic | Multiple Sclerosis experimental autoimmune encephalomyelitis Myelin Oligodendrocyte Glycoprotein Immunomodulatory mechanisms |
| url | https://www.mdpi.com/1467-3045/44/11/388 |
| work_keys_str_mv | AT dariushhaghmorad oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT bahmanyousefi oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT majideslami oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT alirashidypour oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT mahdiehtarahomi oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT maryamjadidtavaf oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT azitasoltanmohammadi oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT siminzargarani oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT aleksandrkamyshnyi oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses AT valentynoksenych oraladministrationofmyelinoligodendrocyteglycoproteinattenuatesexperimentalautoimmuneencephalomyelitisthroughinductionofth2tregcellsandsuppressionofth1th17immuneresponses |